Holen Sie sich die Stockscreener-App
2.88
2.37%
-0.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.95
Offen:
$2.9
24-Stunden-Volumen:
2.63M
Relative Volume:
0.40
Marktkapitalisierung:
$580.67M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.3585
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
-5.26%
1M Leistung:
-12.73%
6M Leistung:
+164.22%
1J Leistung:
+44.00%
1-Tages-Spanne:
$2.84
$2.97
1-Wochen-Bereich:
$2.78
$3.04
52-Wochen-Spanne:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.88 | 683.29M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
126.85 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.62 | 42.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.335 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.45 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.13 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Esperion Appoints New Chief Commercial Officer - TipRanks
Esperion appoints John Harlow as chief commercial officer - Investing.com
Esperion Therapeutics Appoints New Chief Commercial Officer - TradingView
Esperion Appoints John Harlow as Chief Commercial Officer to Drive Growth and Innovation - Quiver Quantitative
Esperion (NASDAQ: ESPR) appoints John Harlow CCO; led 85% revenue growth at Melinta - Stock Titan
Can Esperion Therapeutics Inc. stock double in next 5 years2025 Volatility Report & Safe Capital Preservation Plans - newser.com
Relative strength of Esperion Therapeutics Inc. in sector analysis2025 Winners & Losers & Fast Entry High Yield Tips - newser.com
Why retail investors favor Esperion Therapeutics Inc. stockJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
Smart tools for monitoring Esperion Therapeutics Inc.’s price actionBuy Signal & Safe Capital Investment Plans - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fakeJuly 2025 Intraday Action & Long-Term Safe Investment Plans - newser.com
Can Esperion Therapeutics Inc. stock reach $100 price target2025 Biggest Moves & Long-Term Investment Growth Plans - newser.com
Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Year in Review & Fast Exit and Entry Strategy Plans - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.July 2025 Update & Safe Entry Point Alerts - newser.com
Should you wait for a breakout in Esperion Therapeutics Inc.July 2025 Intraday Action & Community Consensus Trade Alerts - newser.com
How Esperion Therapeutics Inc. stock benefits from global expansion2025 Top Gainers & Technical Pattern Based Signals - newser.com
Will Esperion Therapeutics Inc. stock return to pre crisis levelsQuarterly Market Review & Real-Time Volume Trigger Notifications - newser.com
Using AI based signals to follow Esperion Therapeutics Inc.Quarterly Profit Summary & Weekly High Return Stock Forecasts - newser.com
Will Esperion Therapeutics Inc. stock outperform international peersJuly 2025 Action & Daily Volume Surge Signals - newser.com
Esperion to Participate in Jefferies Global Healthcare ConferenceLondon - The Manila Times
Esperion (NASDAQ: ESPR) to webcast Nov 18 Jefferies Global Healthcare Conference presentation - Stock Titan
Can volume confirm reversal in Esperion Therapeutics Inc.Quarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-11-03 04:49:46 - newser.com
Published on: 2025-11-03 03:31:08 - newser.com
Will Esperion Therapeutics Inc. (0ET) stock benefit from mergersMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockTrade Performance Summary & Target Return Focused Stock Picks - newser.com
Why Esperion Therapeutics Inc. stock is favored by top institutionsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Can Esperion Therapeutics Inc. stock deliver surprise earnings beatMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Published on: 2025-11-03 01:10:01 - newser.com
Why Esperion Therapeutics Inc. is moving todayJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
How high can Esperion Therapeutics Inc. stock goPortfolio Return Summary & Real-Time Buy Signal Alerts - newser.com
Why analysts remain bullish on Esperion Therapeutics Inc. stock2025 Sector Review & Real-Time Market Sentiment Reports - newser.com
Esperion Therapeutics (NASDAQ:ESPR) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Multi asset correlation models including Esperion Therapeutics Inc.Buy Signal & Verified Short-Term Plans - newser.com
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):